LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Viridian Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERVRDN
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / VRDN COVERAGE

What’s moving Viridian Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Up 5.05%

Why Viridian Therapeutics, Inc.’s (VRDN) Stock Is Up 5.05%

Investors are testing whether Viridian Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript

The story matters when it changes Viridian Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates

Investors are testing whether Viridian Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2023 Earnings Call Transcript

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2023 Earnings Call Transcript

Investors are testing whether Viridian Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
05
Viridian Therapeutics, Inc. (VRDN) Q1 2023 Earnings Call Transcript

Viridian Therapeutics, Inc. (VRDN) Q1 2023 Earnings Call Transcript

Investors are testing whether Viridian Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest VRDN filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-05 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-05 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-29 · Period 2026-06-26SEC ↗8-KMaterial company eventFiled 2026-06-03 · Period 2026-06-02SEC ↗8-KMaterial company eventFiled 2026-05-28 · Period 2026-05-27SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-17 · Period 2026-06-02SEC ↗4Official SEC filingFiled 2026-07-02 · Period 2026-07-01SEC ↗
EARNINGS / QUARTERLY TRACKER

Viridian Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.